贝伐珠单抗注射液联合XELOX化疗治疗结直肠癌的临床效果  

Clinical Effect of Bevacizumab Injection Combined with XELOX Chemotherapy in the Treatment of Colorectal Cancer

作　　者：卢翠萍 郑秋香[1] 郑俊琼[1] LU Cuiping;ZHENG Qiuxiang;ZHENG Junqiong(Longyan First Hospital,Longyan 364000,China;不详)

机构地区：[1]龙岩市第一医院,福建龙岩364000

出　　处：《中外医学研究》2021年第33期91-94,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究贝伐珠单抗注射液联合XELOX化疗治疗结直肠癌的临床效果。方法:选取2017年6月-2018年8月本院接收的64例结直肠癌患者作为研究对象,并采用双盲法将其分为对照组(32例,采用XELOX化疗)和研究组(32例,采用贝伐珠单抗注射液联合XELOX化疗)。比较两组的疾病控制率和总有效率、治疗前后的血清CRP水平、疾病无进展生存时间和总生存时间。结果:治疗后,研究组的疾病控制率(71.88%)和总有效率(59.38%)均明显高于对照组(46.88%、31.25%),差异有统计学意义(P<0.05);治疗前,两组的血清CRP水平比较,差异无统计学意义(P>0.05),治疗后,两组血清CRP水平较治疗前均有降低,研究组的血清CRP水平低于对照组,差异有统计学意义(P<0.05);研究组的疾病无进展生存时间和总生存时间均长于对照组,差异有统计学意义(P<0.05)。结论:在结直肠癌患者中采用贝伐珠单抗注射液联合XELOX化疗,能有效控制其疾病进展,降低血清CRP水平,延长生存时间,临床治疗效果显著。Objective:To explore the clinical effect of Bevacizumab Injection combined with XELOX chemotherapy in the treatment of colorectal cancer.Method:A total of 64 patients with colorectal cancer received in our hospital from June 2017 to August 2018 were selected as the study subjects,and they were divided into the control group (32 cases with XELOX chemotherapy) and study group (32 cases with Bevacizumab Injection combined with XELOX chemotherapy) using a double-blind method.The disease control rate and total effective rate,serum CRP levels before and after treatment,disease progression-free survival time and overall survival time were compared between the two groups.Result:After treatment,the disease control rate (71.88%) and total effective rate (59.38%) of the study group were significantly higher than those of the control group (46.88%,31.25%),and the differences were statistically significant (P<0.05);the serum CRP levels of the two groups before treatment were compared,and the difference was not statistically significant (P>0.05);after treatment,the serum CRP levels of the two groups were reduced than that before treatment,and the serum CRP level of the study group was lower than that of the control group,and the differences were statistically significant (P<0.05);the disease progression-free survival time and overall survival time of the study group were longer than those of the control group,and the differences were statistically significant (P<0.05).Conclusion:The use of Bevacizumab Injection combined with XELOX chemotherapy in patients with colorectal cancer can effectively control the disease progression,reduce serum CRP levels,extend survival time,and have significant clinical treatment effects.

关 键 词：结直肠癌 贝伐珠单抗注射液 XELOX化疗 血清CRP 生存时间 

分 类 号：R735.34[医药卫生—肿瘤]